LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
Myriam Chalabi, Y.L. Verschoor, J. van den Berg, Karolina Sikorska, Geerard L. Beets, Anja van Lent, M.C. Grootscholten, A. Aalbers, N. Buller, Hendrik A. Marsman, Eduard R. Hendriks, Pim Burger, T. Aukema, Steven J. Oosterling, Regina G. H. Beets‐Tan, Ton N. Schumacher, Monique E. van Leerdam, E.E. Voest, J.B.A.G. Haanen
Topics & Concepts
MedicineIpilimumabNivolumabInternal medicineOncologyPopulationClinical endpointColorectal cancerNeoadjuvant therapyAdjuvantCancerSurrogate endpointStage (stratigraphy)ImmunotherapyGastroenterologySurgeryClinical trialBreast cancerBiologyEnvironmental healthPaleontologyColorectal and Anal CarcinomasCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies